Residential building permits in the US dropped 1.7% over the year ending July 2026, running 19.4% below the pre-pandemic trend, signaling a worsening housing shortage. Detached single-family home completions fell 2.5% in 2025, marking the third consecutive annual decline and the lowest since 2020. Builders are responding by constructing smaller homes faster to maintain affordability, but the reduced pipeline risks tightening the market and driving prices higher when demand returns. Regional permit declines are concentrated in Sun Belt cities, while some coastal and Midwest markets see gains after years of subdued construction.
The new home construction boom is running out of steam, with Pluang's snapshot as of Sep 14, 2026 19:14 WIB showing mixed performance among US Real Estate stocks. Of 22 priced Real Estate-sector US stocks tradable on Pluang, 11 rose and 8 fell today. Notable movers include Realty Income Corp (O) at USD 59.94 with a +0.74% change, VICI Properties Inc (VICI) at USD 25.00 with +0.68%, and Public Storage (PSA) at USD 298.50 with +0.67%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
